Drug Profile
CS 6253
Alternative Names: Cogpep™; CS-6253Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator University of California at Berkeley
- Developer Artery Therapeutics; Tel Aviv University; University of California at Berkeley
- Class Antidementias; Antihyperglycaemics; Neuropeptides; Vascular disorder therapies
- Mechanism of Action ATP binding cassette transporter 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
- No development reported Atherosclerosis; Type 2 diabetes mellitus
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Intraperitoneal, Injection)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Atherosclerosis in USA (SC, Injection)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (SC, Injection)